---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-074318"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:34:16.816309+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Longeveron closes $5.0M public offering (up to $17.5M with warrants) for laromestrocel development

## Summary
- Gross proceeds $5.0M upfront from offering of ~5.88M shares/pre-funded warrants and 14.7M short-term warrants at $0.85 combined price.
- Potential additional $12.5M if short-term warrants (exercisable at $0.85, 24-month term) are fully cash-exercised.
- Proceeds to fund clinical/regulatory development of laromestrocel for HLHS, Alzheimer's, pediatric DCM, and BLA readiness.
- Placement agent H.C. Wainwright received 7% cash fee plus warrants at $1.0625; board members and insiders participated.
- Company subject to 60-day equity issuance lock-up and one-year variable rate transaction ban.

## SEC filing metadata
- accession: 0001213900-25-074318
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390025074318/0001213900-25-074318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390025074318/ea0252590-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-074318
- JSON: https://secwatch.observer/filing/0001213900-25-074318.json
- Plain text: https://secwatch.observer/filing/0001213900-25-074318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.